Pure Biologics S.A. Logo

Pure Biologics S.A.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Pure Biologics S.A. is a biopharmaceutical company specializing in the discovery and development of innovative biological drugs and non-systemic therapies. The company's core focus is on creating novel, non-biosimilar therapeutic molecules, primarily utilizing antibody and aptamer technologies. Its therapeutic portfolio targets significant unmet medical needs, with a primary emphasis on immuno-oncology and autoimmunity. Pure Biologics also engages in the research and development of diagnostic tests and medical devices for therapeutic applications. The company aims to develop molecules that activate the immune system to combat cancer and other diseases, positioning itself as a key player in the development of next-generation biological treatments.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Pure Biologics S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-27 17:34
Share Issue/Capital Change
Przydział akcji zwykłych na okaziciela serii P1 - Content (PL)
Polish 954 bytes
2025-07-18 15:21
Share Issue/Capital Change
Zawarcie umowy inwestycyjnej z ACRX Investments Limited - Content (PL)
Polish 3.3 KB
2025-07-10 22:52
Regulatory News Service
Rejestracja akcji na okaziciela serii N w depozycie papierów wartościowych prow…
Polish 1.1 KB
2025-07-09 18:52
Share Issue/Capital Change
Podjęcie przez Zarząd Spółki uchwały w sprawie ustalenia ceny emisyjnej oraz ha…
Polish 1.1 KB
2025-07-08 18:35
Share Issue/Capital Change
Treść uchwały nr 17 ZWZ z dnia 30 czerwca 2025 r.
Polish 156.3 KB
2025-07-08 18:35
Post-Annual General Meeting Information
Korekta raportu bieżącego nr 23/2025 w sprawie treści uchwał podjętych przez Zw…
Polish 1.7 KB
2025-06-30 18:05
Declaration of Voting Results & Voting Rights Announcements
Lista Akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zg…
Polish 1.5 KB
2025-06-30 17:38
Post-Annual General Meeting Information
Treść uchwał podjętych przez ZWZ Spółki w dniu 30 czerwca 2025 r.
Polish 352.3 KB
2025-06-30 17:38
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Pure Biologics S.A. 3…
Polish 766 bytes
2025-06-30 10:04
Capital/Financing Update
Rozpoczęcie negocjacji z ACRX Investments - Content (PL)
Polish 1.3 KB
2025-06-26 19:07
Legal Proceedings Report
Złożenie przez Zarząd wniosku o ogłoszenie upadłości Spółki - Content (PL)
Polish 1.8 KB
2025-06-23 15:13
Regulatory News Service
Sprzedaż spółki DOTO MEDICAL sp. z o.o. oraz platformy aptamerowej - Content (P…
Polish 1.3 KB
2025-06-05 19:43
Legal Proceedings Report
Potwierdzenie rozwiązania umów o dofinansowanie - Content (PL)
Polish 1.8 KB
2025-06-03 20:25
Board/Management Information
Sprawozdanie Rady Nadzorczej Spółki za rok 2024
Polish 643.7 KB
2025-06-03 20:25
Post-Annual General Meeting Information
Projekty uchwał ZWZ Spółki zwołanego na dzień 30.06.2025
Polish 328.0 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN